Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Long Term Follow up Dry Eye Disease: early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Long Term Follow up Dry Eye Disease: 1 US clinical trial tracked, none currently recruiting.

Long Term Follow up Dry Eye Disease is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Oyster Point Pharma, running 1 of these trials.

Enrollment posture brief

Registry condition long-term-follow-up-dry-eye-disease

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Long Term Follow up Dry (th…0%
Open-enrollment share among volume-matched conditions near Long Term Follow up Dry Eye Disease

Long Term Follow up Dry Eye Disease has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Long Term Follow up Dry Eye Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Long Term Follow up Dry Eye Disease is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on Long Term Follow up Dry Eye Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo (vehicle) nasal spray Drug
1 trials
OC-01 High Dose, 1.2 mg/mL Drug
1 trials
OC-01 Mid Dose, 0.6 mg/mL Drug
1 trials
OC-01 Low Dose, 0.12 mg/mL Drug
1 trials

US sites by state

Facility locations filed on Long Term Follow up Dry Eye Disease trials. A trial with sites in several states counts in each.

Massachusetts 1 trials
Indiana 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Long Term Follow up Dry Eye Disease page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Long Term Follow up Dry Eye Disease trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Oyster Point Pharma sponsors the most Long Term Follow up Dry Eye Disease trials on record, review their full trial history before evaluating a specific study. See Oyster Point Pharma's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Long Term Follow up Dry Eye Disease condition card totals 1 registered trials; most-linked intervention Placebo (vehicle) nasal spray; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.